GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ProMIS Neurosciences Inc (NAS:PMN) » Definitions » Market Cap

PMN (ProMIS Neurosciences) Market Cap : $30.40 Mil (As of Dec. 15, 2024)


View and export this data going back to 2005. Start your Free Trial

What is ProMIS Neurosciences Market Cap?

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). ProMIS Neurosciences's share price for the quarter that ended in Sep. 2024 was $1.25. ProMIS Neurosciences's Shares Outstanding (EOP) for the quarter that ended in Sep. 2024 was 32.69 Mil. Therefore, ProMIS Neurosciences's market cap for the quarter that ended in Sep. 2024 was $40.86 Mil.

ProMIS Neurosciences's quarterly market cap declined from Mar. 2024 ($36.22 Mil) to Jun. 2024 ($28.44 Mil) but then increased from Jun. 2024 ($28.44 Mil) to Sep. 2024 ($40.86 Mil).

ProMIS Neurosciences's annual market cap declined from Dec. 2021 ($49.17 Mil) to Dec. 2022 ($37.23 Mil) and declined from Dec. 2022 ($37.23 Mil) to Dec. 2023 ($21.72 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. ProMIS Neurosciences's Enterprise Value for Today is $8.83 Mil.


ProMIS Neurosciences Market Cap Historical Data

The historical data trend for ProMIS Neurosciences's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ProMIS Neurosciences Market Cap Chart

ProMIS Neurosciences Annual Data
Trend Mar14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Market Cap
Get a 7-Day Free Trial Premium Member Only Premium Member Only 36.63 24.02 49.17 37.23 21.72

ProMIS Neurosciences Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Market Cap Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 36.69 21.72 36.22 28.44 40.86

Competitive Comparison of ProMIS Neurosciences's Market Cap

For the Biotechnology subindustry, ProMIS Neurosciences's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ProMIS Neurosciences's Market Cap Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ProMIS Neurosciences's Market Cap distribution charts can be found below:

* The bar in red indicates where ProMIS Neurosciences's Market Cap falls into.



ProMIS Neurosciences Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

ProMIS Neurosciences's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as

Market Cap (A: Dec. 2023 )=Share Price (A: Dec. 2023 )*Shares Outstanding (EOP) (A: Dec. 2023 )
=$1.15*18.8853
=$21.72

ProMIS Neurosciences's Market Cap for the quarter that ended in Sep. 2024 is calculated as

Market Cap (Q: Sep. 2024 )=Share Price (Q: Sep. 2024 )*Shares Outstanding (EOP) (Q: Sep. 2024 )
=$1.25*32.6892
=$40.86

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ProMIS Neurosciences  (NAS:PMN) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the company’s debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.


ProMIS Neurosciences Market Cap Related Terms

Thank you for viewing the detailed overview of ProMIS Neurosciences's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.


ProMIS Neurosciences Business Description

Traded in Other Exchanges
Address
1920 Yonge Street, Suite 200, Toronto, ON, CAN, M4S 3E2
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine is based on the use of two complementary techniques. The company applies its thermodynamic, computational discovery platform-ProMIS and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.
Executives
Madge K. Shafmaster director C/O PROMIS NEUROSCIENCES INC., SUITE 200, 1920 YONGE STREET, TORONTO A6 M4S 3E2
Patrick D. Kirwin director C/O PROMIS NEUROSCIENCES INC., SUITE 200, 1920 YONGE STREET, TORONTO A6 M4S 3E2
Larry Douglas Altstiel officer: Chief Medical Officer C/O NEUROTROPE, INC., 50 PARK PLACE, SUITE 1401, NEWARK NJ 07102
Daniel E. Geffken officer: Chief Financial Officer DAMONMILL SQUARE, SUITE 6A, CONCORD MA 01742
Jeremy M. Sclar 10 percent owner 33 BOYLSTON STREET, SUITE 3000, CHESTNUT HILL MA 02467
Gail M Farfel director, officer: Chief Executive Officer 142 TEMPLE STREET, SUITE 205, NEW HAVEN CT 06510
Max A. Milbury officer: Principal Accounting Officer C/O PROMIS NEUROSCIENCES INC., SUITE 200, 1920 YONGE STREET, TORONTO A6 M4S 3E2
Gavin T. Malenfant officer: Chief Operating Officer C/O PROMIS NEUROSCIENCES INC., SUITE 200, 1920 YONGE STREET, TORONTO A6 M4S 3E2
Neil Cashman director, officer: Chief Scientific Officer C/O PROMIS NEUROSCIENCES INC., SUITE 200, 1920 YONGE STREET, TORONTO A6 M4S 3E2
Johanne Kaplan officer: Chief Development Officer PROMIS NEUROSCIENCES INC., SUITE 200, 1920 YONGE STREET, TORONTO A6 M4S 3E2
Eugene Williams director, officer: Chairman and CEO C/O PROMIS NEUROSCIENCES INC., SUITE 200, 1920 YONGE STREET, TORONTO A6 M4S 3E2
Richard J. Gregory director 830 WINTER STREET, WALTHAM MA 02451
Neil K Warma director C/O PROMIS NEUROSCIENCES INC., SUITE 200, 1920 YONGE STREET, TORONTO A6 M4S 3E2
William W Wyman director 4 N. BALCH STREET, HANOVER NH 03755
Josh Mandel-brehm director C/O PROMIS NEUROSCIENCES INC., SUITE 200, 1920 YONGE STREET, TORONTO A6 M4S 3E2